• Users Online: 502
  • Print this page
  • Email this page
CASE REPORT
Year : 2023  |  Volume : 3  |  Issue : 2  |  Page : 430-432

Off-label use of intravitreal brolucizumab injection for fibrinous central serous chorioretinopathy: A case report


1 Retina Institute of Bengal, Siliguri, West Bengal, India
2 Department of Vitreoretinal Services, Shantilal Shanghvi Eye Institute, Mumbai, Maharashtra, India

Correspondence Address:
Somnath Chakraborty
Retina Institute of Bengal, Pradhan Nagar, Siliguri - 734 003, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_2041_22

Rights and Permissions

The authors describe the first case report of management of central serous chorioretinopathy (CSCR) associated with subretinal fibrin deposition by intravitreal injection (IVI) of brolucizumab in a 45-year-old male. At 3 months, his best-corrected visual acuity (BCVA) improved from 20/200 to 20/80. On fundus evaluation, there was complete resolution of the subretinal fluid (SRF) and fibrin, which was confirmed on spectral-domain optical coherence tomography (SD-OCT). There were no reports of ocular or systemic adverse effects. Increased flux and permeability of the retinal pigment epithelium secondary to anti-vascular endothelial factor (anti-VEGF) injection agent can explain the migration of the fibrin toward the choroid and its resolution. Further molecular and clinical studies are warranted to better understand the role of brolucizumab in the management of fibrinous CSCR.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed194    
    Printed4    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal